Immunogenicity Testing For Biosimilars
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing costs while providing patients with…
The State Of The Biosimilars Market
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a significant number of top-selling drugs…
Difference Between Biobetters and Biosimilars
According to research compiled by Reports and Data, in 2018 the global biologics market was valued at over $250 million, but is projected to reach…
Answers to Your Questions on Immunogenicity Testing for Biosimilars: Part 2
BioAgilytix’s Todd Lester answers additional questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.
Questions on Immunogenicity Testing for Biosimilars Answered: Part 1
BioAgilytix’s Todd Lester answers questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.
Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices
BioAgilytix has been fortunate enough to have several of our team members participate as co-authors on all three AAPS white papers in the series on…